查看文章

The search for new drugs against fungal infections is a major challenge to current research in mycotic diseases. Among the different types of drugs prevailing in the market antifungal antibiotics though low in number but have an important role in the control of mycotic diseases. The need for new, safe and more effective antifungal is a major challenge to the pharmaceutical industry today, especially with the increase in opportunistic infections in the immune-compromised host. In recent years the microorganisms have become important in the study of novel microbial products exhibiting antimicrobial, antiviral, antitumor as well as anticoagulant and cardioactive properties. Actinomycetes have occupied a prominent position in the pharmaceutical industry for their seemingly unlimited capacity to produce secondary metabolites. The use of Actinomycetes as an anti fungal agent in the past is mostly responsible for its popularity with antibiotic research today. The use of bacteria as an antifungal agent has been widely explored by the scientific community with the initial report of its use for patients with candidiasis. The relevance of iron for many pathogenic Actinomycetes for their intracellular survival and the immense potential of targeting iron-sulfur (Fe-S) cluster containing proteins for the drug discovery also holds a great therapeutic significance. Considering the immense potential of these Actinomycetes in the discovery of novel lead compounds and for exploitation in pharmaceutical, agriculture and other industrial mechanisms applications, current review will further enhance our understanding of secondary metabolites derived from Actinomycetes, iron …